Additional Study Information: The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will receive Nivolumab infused through a vein in your arm every 4 weeks, for a total of 12 doses. You will receive these doses over a 48 week period.